Mitoxantrone-Etoposide or HD-ARA-C/Mitoxantrone for Remission Induction in Children with First Relapse of AML
One third of children with AML, initially responding to chemotherapy encounter recurrence of their disease. An effective chemotherapeutic regimen with tolerable toxicity is needed for this group of heavily pretreated children. In the past AML-BFM protocols did not specify for a salvage therapy. Reinduction chemotherapy with High Dose Ara-C/Mitoxantrone (HAM) or Mitoxantrone/Etoposide (Mitox/VP) was proposed. We performed a retrospective analysis among patients with first relapse previously treated with the AML-BFM 87 protocol with respect to initial response rates, toxicity and long term survival comparing the different reinduction regimen.
KeywordsSalvage Therapy Cytosine Arabinoside Remission Induction Postremission Therapy Initial Response Rate
Unable to display preview. Download preview PDF.
- 3.Movassaghi N, Higgins G, Pyesmany A, Baehner R, Chard R, Sather H, Hammond D Evaluation of Cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with Cytosine Arabinoside: A Report from Children’s Cancer Study Group. Med. Ped. Oncol. (1984) 12:352–356CrossRefGoogle Scholar
- 5.Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T: Definition of refractoriness against conventional chemotherapy in acute myelogenous Leukemia: A proposal based on the results of retreatment by Thioguanine, Cytosine Arabinoside, and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4, (1990) 184–188PubMedGoogle Scholar
- 6.Kantarjian HM, Keatin MJ, Walters RS, McCredie KB, Freireich EJ: The characteristics and outcome of patients with late relapse acute myelogenous leukemia. JCO (1988) 6: 232–238Google Scholar